Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2476 to 2490 of 8910 results

  1. Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development Reference number: GID-TA11487 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    Awaiting development Reference number: GID-TA11100 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Efzimfotase alfa for treating hypophosphatasia [ID6633]

    Awaiting development Reference number: GID-TA11838 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [TSID12331]

    Awaiting development Reference number: GID-TA11936 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [ID6704]

    Awaiting development Reference number: GID-TA11948 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Orforglipron for managing overweight and obesity ID6516

    In development Reference number: GID-TA11650 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    Awaiting development Reference number: GID-TA11509 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Surgical mesh for ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date: TBC

    Health technology evaluations
    In development

  9. Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [TSID12341]

    Awaiting development Reference number: GID-TA11941 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Bictegravir-Lenacapavir for HIV-1 infection [TSID12343]

    Awaiting development Reference number: GID-TA11943 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Suspected Cancer: recognition and referral (update)

    In development Reference number: GID-NG10443 Expected publication date:  25 March 2026

    NICE guideline
    In development

  12. Guidance on the use of electroconvulsive therapy: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 16 February 2026.

    Technology appraisal guidance
    In consultation

  13. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]

    In development Reference number: GID-TA11742 Expected publication date:  05 August 2026

    Technology appraisal guidance
    In development

  14. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation